These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 11926715)

  • 1. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
    Kennedy SH; McCann SM; Masellis M; McIntyre RS; Raskin J; McKay G; Baker GB
    J Clin Psychiatry; 2002 Mar; 63(3):181-6. PubMed ID: 11926715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series.
    Paslakis G; Gilles M; Deuschle M
    J Clin Psychopharmacol; 2010 Aug; 30(4):473-4. PubMed ID: 20631572
    [No Abstract]   [Full Text] [Related]  

  • 4. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction.
    Clayton AH; McGarvey EL; Abouesh AI; Pinkerton RC
    J Clin Psychiatry; 2001 Mar; 62(3):185-90. PubMed ID: 11305705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
    Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
    Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Pharmacol; 2000 Jan; 40(1):58-66. PubMed ID: 10631623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.
    Modell JG; Katholi CR; Modell JD; DePalma RL
    Clin Pharmacol Ther; 1997 Apr; 61(4):476-87. PubMed ID: 9129565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
    Corya SA; Williamson D; Sanger TM; Briggs SD; Case M; Tollefson G
    Depress Anxiety; 2006; 23(6):364-72. PubMed ID: 16710853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
    Desmarais JE; Looper KJ
    J Clin Psychiatry; 2009 Dec; 70(12):1688-97. PubMed ID: 20141708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.
    Mansoor B; Rengasamy M; Hilton R; Porta G; He J; Spirito A; Emslie GJ; Mayes TL; Clarke G; Wagner KD; Shamseddeen W; Birmaher B; Ryan N; Brent D
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):458-67. PubMed ID: 24024532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
    Rush AJ; Trivedi MH; Wisniewski SR; Stewart JW; Nierenberg AA; Thase ME; Ritz L; Biggs MM; Warden D; Luther JF; Shores-Wilson K; Niederehe G; Fava M;
    N Engl J Med; 2006 Mar; 354(12):1231-42. PubMed ID: 16554525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea.
    DeVane CL
    J Clin Psychiatry; 2003; 64 Suppl 18():14-9. PubMed ID: 14700450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.
    Meyer JH; Wilson AA; Sagrati S; Hussey D; Carella A; Potter WZ; Ginovart N; Spencer EP; Cheok A; Houle S
    Am J Psychiatry; 2004 May; 161(5):826-35. PubMed ID: 15121647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of sexual dysfunction among newer antidepressants.
    Clayton AH; Pradko JF; Croft HA; Montano CB; Leadbetter RA; Bolden-Watson C; Bass KI; Donahue RM; Jamerson BD; Metz A
    J Clin Psychiatry; 2002 Apr; 63(4):357-66. PubMed ID: 12000211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sexual function during bupropion or paroxetine treatment of major depressive disorder.
    Kennedy SH; Fulton KA; Bagby RM; Greene AL; Cohen NL; Rafi-Tari S
    Can J Psychiatry; 2006 Mar; 51(4):234-42. PubMed ID: 16629348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
    J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.
    Kennedy SH; Eisfeld BS; Dickens SE; Bacchiochi JR; Bagby RM
    J Clin Psychiatry; 2000 Apr; 61(4):276-81. PubMed ID: 10830148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
    Kaplan EM
    Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
    Denys D; van der Wee N; van Megen HJ; Westenberg HG
    J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.